Translate

Kidney Transplant Industry and Market studies, Numbers & Forecast for United States, Mexico & Canada

"Kidney Transplant Market, Numbers & Forecast for United States, Mexico & Canada" The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect.

Description-

The improvement in technology, surgical techniques and immunosuppressive drugs, Kidney transplantation has became the preferred treatment for chronic kidney disease for many people. A transplant may offer the best chance of returning to a more normal life. Kidney transplantation has increasingly become a pivotal intervention for thousands of patients suffering from fatal end stage kidney disease (ESRD).

North America is one of the biggest kidney transplant market in the world. The overall number of Kidney Transplant done in North America (United States, Mexico and Canada) was more than 20 Thousand in 2014. United States is the leader in kidney transplant market in North America. Canada has the least number of kidney transplant done in comparison to United States and Mexico. Despite its high medical cost today United States Kidney Transplant Market is a Billion US$ industry.


All the 3 Countries studied in the report are as follows
 
  1. United States
  2. Canada 
  3. Mexico

All the 6 Kidney Transplant Immunosuppressant) drugs studied in the report are as follows

  1. CellCept (MycophenolateMofetil) 
  2. Prograf (Tacrolimus)
  3. Rapamune (Sirolimus) 
  4. Myfortic (Mycophenolic Acid) 
  5. Neoral / Sandimmune (Cyclosporine) 
  6. Zortress / Certican (Everolimus)

Data Sources 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts. 

For More Information Kindly Contact:

ResearchMoz Global Pvt. Ltd.

90 State Street,
Albany, NY 12207,
United States
http://www.researchmoz.us,Blog - http://bit.ly/2b1Ayn6 866-997-4948 (Us-Canada Toll Free),
+1-518-621-2074,
Email to: sales@researchmoz.us,

Comments